Navigation Links
Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Date:5/7/2009

NEW HAVEN, Conn., May 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that researchers will be presenting two presentations and two posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Helsinki, Finland from May 16-19, 2009.

Independent researchers, Dr. Franciose van Bambeke and Dr. Sandrine Lemaire, both from Universite Catholique de Louvain, will each make oral presentations describing the unique microbiological and pharmacodynamic properties of Rib-X's novel oxazolidinone, radezolid, during a session entitled Pharmacokinetics/Pharmacodynamics: Clinical Relevance, on Saturday, May 16th.

Additionally, Rib-X researchers will be presenting two posters on delafloxacin, one of which discusses the activity and efficacy of delafloxacin in a Phase 2 clinical trial for complicated Skin and Skin Structure Infections. The second poster session details the in vitro activity of delafloxacin against a large, worldwide panel of methicillin-resistant Staphylococcus aureus.

    Details on the presentations and abstracts are as follows:

     Date        Time    Session          Title                Location/Poster

    May 16,    3:06pm -   PK/PD:     The novel oxazolidinone   Lecture Hall 3a
     2009      3:18pm     Clinical   radezolid (RX-1741)
                          Relevance  accumulates in THP-1
                                     macrophages: comparative
                                     studies with linezolid
                                     and azithromycin.

    May 16,    3:18pm -   PK/PD:     Radezolid (RX-1741), a    Lecture Hall 3a
     2009      3:30pm     Clinical   novel oxazolidinone, is
                          Relev
'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
2. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
3. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
4. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
11. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property development ... intellectual property, announced today that the Markman hearing ... the U.S. District Court for the Northern District ... rescheduled for November 10, 2014.  This hearing was ... Order setting the Markman date was received after ...
(Date:10/1/2014)... September 30, 2014 The participants committed ... but to spending their own time adjusting, tweaking and ... complex designs were ready for judging. , “I enjoyed ... firm thought leader. “The entries showed a commendable ... physical characteristics of the print medium and the creativity ...
(Date:10/1/2014)... New applications of structures and materials ... in nature over millennia are featured in a ... applications in biophotonics in the October issue of the ... published by SPIE, the international society for optics and ... peer-reviewed articles are accessible via open access. , “Biomimetic ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 TeselaGen ... National Science Foundation to expand their bioCAD/CAM software suite, ... and modify DNA. The Small Business Innovation Research Phase ... “j5” technology under exclusive license from the Lawrence Berkeley ... BioEnergy Institute , an LBNL laboratory that develops alternative ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Array Architects Challenges Staff to Create with 3D Printer 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Dec. 13 BioMed Realty Trust, Inc.,(NYSE: BMR ... to its,board of directors, increasing the board to eight ... real estate industry, with a breadth of,ability and experience ... real estate projects. We believe that,Rick,s contributions to our ...
... new validation studies,were published during 2007 on the ... number of studies published to 65., "This ... interest from US and,European institutes" said Gary Zamler, ... academic medical institutions and teaching hospitals,have completed studies ...
... retired $12.83 million in existing current 2008 convertible notes, and extended the ... ... convertible notes, SEATTLE, Dec. 13 Cell Therapeutics, Inc.,("CTI" or the ... of its new 5.75% Convertible Senior,Notes (the "New Notes") due 2011 and ...
Cached Biology Technology:BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 32007 a "Record Year" for Successful Validation Studies of Simbionix Simulators 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3
(Date:10/1/2014)... to take a healthy salad up a level by ... cancer in leafy greens. , "In the long run, ... eating the salad or making a pill from the ... engineering at Case Western Reserve School of Medicine and ... breast cancer organization is funding the research with a ...
(Date:10/1/2014)... 2014 Neuartiger Detektionstechnologie ... Die Biowissenschaften erlebten in den ... Detektionstechnologien. Einige davon sind Senkrechtstarter und andere ... ist eine neuartige Detektionstechnologie, die von Forschern ... wurde. Jetzt ist diese Technologie endlich auf ...
(Date:10/1/2014)... , October 1, 2014 ... the life science field  The life ... and go over the years. Some are shooting ... upconversion is a novel detection technology that has ... Now, finally, this technology is becoming commercially available. ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First-of-a-kind Solution for Utilizing Photon Upconversion 2
... For those living with gastrointestinal disorders, such as ulcers or ... or dietary changes. But what if one day treatment meant ... free of inflamed or diseased tissues? That is ... Institute of Technology (MIT) are hoping their new study findings ...
... The winners of NERC,s inaugural short article and photography ... London this evening. The winning essay, by Laura ... excitement she felt during a recent research voyage when ... black smoke across her monitoring screens. These are underwater ...
... the 20th International AIDS Conference (AIDS 2014) to be ... today announced 19 major plenary presentations, focusing on the primary ... sessions will open each day of the conference, which is ... 200 countries. "We are excited to have such ...
Cached Biology News:Manufacturing a new gut to treat GI diseases 2NERC announces the winner of its first photo and essay competition 2NERC announces the winner of its first photo and essay competition 320th International AIDS Conference (AIDS 2014) plenary speakers announced 220th International AIDS Conference (AIDS 2014) plenary speakers announced 3
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
...
... sufficient materials for 1,464 array sample elements. , ... , Blocker BSA in PBS (10X): 50 ... 10 g , BupH Phosphate Buffered ... 2 x 10 ml ampules , SuperSignal West ...
... Obtain Clean and Accurate Results Laser ... increase the sensitivity and accuracy of molecular ... cell types and multi-cellular structures isolated from ... approach to microdissection-developed in 1996 at the ...
Biology Products: